Vigil Neuroscience Inc (VIGL)
| Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
| Industry • Biotechnology & Pharmaceuticals |
| Sector • Healthcare |
The company created positive scenario for the shareholders, posting an important rise in fourth quarter of 2022 earnings season with operating loss of $-18.873 millions
VIGL announced fourth quarter of 2022 operating loss of $-18.873 millions
Published Mar 22 2023
Goran Soko / CSIMarket.com Contributer
![closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons")
The Biotechnology & Pharmaceuticals sector reporters continue to analyze the fourth quarter of 2022 performance. Today those reporters follow operating loss of $-18.873 millions, from the company, which hasn't mentioned any revenue thus far, for the respective October to December 31 2022 reporting season. Now, it's apparent that, the ascending business managed to work more competently, then in the fiscal three months ending December 31 2021. Coming from operating loss of $-68.884 millions.
Eventually, there was mitigation on the net loss. where the deficit has been trimmed from the period, a year prior. It is a main take away from thefourth quarter of 2022 earnings season. Loss was $-18.456 millions, while in the fourth quarter of 2022 $-68.305 millions.
Vigil Neuroscience Inc is expected to report next financial earnings on May 11, 2023.